Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL [Phase 2]
Phase 2 trial testing large fraction radiotherapy in combination with lenalidomide and glofitamab for relapsed/refractory diffuse large B-ce…
-
CLINICAL_TRIALS trial_result · 2025-07-22Clinical Trial Update: FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up
A completed follow-up update on fertility outcomes after intensive lymphoma therapy in young women enrolled in LNH-03 and LNH-07 trials for …
-
CLINICAL_TRIALS other · 2025-07-18Clinical Trial Update: Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL [NA]
This clinical trial update reports a study evaluating a quadruple combo regimen of pomalidomide, rituximab, orelabrutinib, and polatuzumab v…
-
CLINICAL_TRIALS trial_result · 2025-07-17Clinical Trial Update: A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2, Phase 3]
A Phase 2/Phase 3 trial compared tafasitamab plus bendamustine to rituximab plus bendamustine in adults with relapsed or refractory diffuse …
-
CLINICAL_TRIALS research · 2025-07-17Clinical Trial Update: Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
A clinical trial update from Fudan University shows recruiting to evaluate whether combining ctDNA analysis with PET can predict response to…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma
A completed follow-up study evaluating a CD19 CAR-T cell therapy engineered to express IL7 and CCL19 for relapsed or refractory B-cell lymph…
-
CLINICAL_TRIALS research · 2025-07-16Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) [Phase 1]
Phase 1 LOTIS-10 study assessing the pharmacokinetics and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell ly…
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: ImmunoMRI for Assessment of Tumor-associated Macrophages [EARLY_Phase 1]
A Phase 1 clinical trial update evaluating ImmunoMRI as a biomarker to assess tumor-associated macrophages in diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
An observational multicenter study sponsored by AstraZeneca to understand the clinical characteristics, treatment patterns, and access to no…
-
CLINICAL_TRIALS trial_result · 2025-07-14Clinical Trial Update: Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study of AUTO3, a CD19/CD22 CAR T-cell therapy, for relapsed/refractory diffuse large B-cell lymphoma; the trial has terminated wi…
-
CLINICAL_TRIALS research · 2025-07-14Clinical Trial Update: Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL [Phase 2]
Phase 2 trial evaluating glofitamab as a bridging therapy to autologous stem cell transplantation for patients with relapsed or refractory d…
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Prospective clinical trial at Ain Shams University investigating whether inflammatory biomarkers (CRP, albumin, CAR, and mGPS) predict treat…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement [Phase 2]
Phase 2 trial results evaluating a chemoimmunotherapy combination for systemic diffuse large B-cell lymphoma with CNS involvement. The study…
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]
The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…
-
CLINICAL_TRIALS research · 2025-07-03Clinical Trial Update: Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma [Phase 1]
Phase 1 clinical trial investigating tumor-associated antigen-specific T cells (TAA-T) in combination with a PD-1 inhibitor for Hodgkin lymp…
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 1]
This is a first-in-human Phase 1 trial evaluating OT-C001, amplified/activated allogeneic natural killer cells, in patients with relapsed/re…
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma [EARLY_Phase 1]
This early-phase study tests daratumumab with dose-adjusted EPOCH for plasmablastic lymphoma and diffuse large B-cell lymphoma across stages…
-
CLINICAL_TRIALS trial_result · 2025-06-27Clinical Trial Update: Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
This completed trial update reports on cardiotoxicity and other late effects after radiotherapy combined with immuno-chemotherapy in non-Hod…
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders [Phase 2]
Phase 2 clinical trial evaluating myeloablative allogeneic hematopoietic stem cell transplantation from related or unrelated donors for a br…
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 [Phase 2]
A Phase II clinical trial evaluating 4 versus 6 cycles of CHP in combination with Polatuzumab vedotin and Rituximab for previously untreated…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation [Phase 2]
Phase 2 clinical trial evaluating Polatuzumab Vedotin in combination with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as salvage …
-
FDA label_change · 2025-06-18FDA Approved: MONJUVI — Supplemental Application (Incyte Corporation)
FDA approved a supplemental application for MONJUVI (tafasitamab-cxix) from Incyte, resulting in changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: A Phase 1 Study of ADI-001 in B Cell Malignancies [Phase 1]
The Phase 1 study of ADI-001 in B cell malignancies has been terminated.
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a bispecific antibody-based salvage therapy followed by CAR-T cell therapy, with or without autologous ste…
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 study of JWCAR239 for B-cell non-Hodgkin lymphoma is not yet recruiting, with indications including diffuse large B-cell lymphoma, f…